Our genes determine how susceptible we are to life-threatening infection. When a patient is already sick, different genetic factors determine how likely they are to survive. The GenOMICC (Genetics of Susceptibility and Mortality in Critical Care) study will identify the specific genes that cause some people to be susceptible to specific infections and consequences of severe injury. Our hope is that identifying these genes will help us to use existing treatments better, and to design new treatments to help people survive ...

GO TO STUDY

Tremor can be both physically and socially challenging. By far the two commonest causes are Essential tremor and Parkinson’s. Oral medication is available but many patients eventually discontinue the drugs used for tremor, due to limited efficacy and unacceptable side effects. For those with severe symptoms, deep brain stimulation can be effective. However, this is not without expense, risk or side-effects, and its effectiveness may reduce over time. Accordingly, there is a need for less invasive stimulation approaches than deep ...

GO TO STUDY

The Tessa Jowell BRAIN MATRIX is a programme of work, the principal purpose of which is to improve the knowledge of, and treatment for, glioma, a type of brain tumour. The programme will include a Platform Study and subsequent interventional clinical trials. This protocol is for the Platform Study, in which a backbone data-repository of disease, treatment and outcome data are collected which will deliver the study’s objectives. Gliomas are the most common primary tumour of the central nervous system (CNS). ...

GO TO STUDY

This project asks: What is the best technology a surgeon can use to remove as much brain cancer as possible, whilst minimising risk of damage to brain function and improving patient quality of life? For patients with a brain tumour called Glioblastoma (GB) prolonging survival whilst ensuring quality of life are key, but remain challenging. GB is incurable and the most frequent and aggressive form of brain cancer, with an extremely poor prognosis both in quality and length of life. ...

GO TO STUDY

REMAP-CAP is a trial designed by clinicians who cared for patients and conducted research during the 2009 H1N1 pandemic. Planning began in 2011. REMAP-CAP builds on the combined input of the world’s leading ICU trial networks. These networks have enrolled tens of thousands of patients into trials. They have extensive experience designing, conducting, and reporting clinical trials that enroll patients who are severely ill. Our goal is to generate evidence that can be applied during the pandemic to reduce mortality or reduce ...

GO TO STUDY

The purpose of this study is to find out if two new treatment cancer vaccines called SCIB1 and iSCIB1+ can be used safely when added to nivolumab (Opdivo) with ipilimumab (Yervoy), or SCIB1 with pembrolizumab (Keytruda). Pembrolizumab or nivolumab with ipilimumab are standard treatments already approved in the UK for the treatment of advanced melanoma (skin cancer). These standard treatments are antibody treatments for cancer. The study will also look to see if SCIB1 or iSCIB1+ can increase the likelihood that ...

GO TO STUDY

SIOP-HRMB is an international phase III clinical trial in children, young people and adults with high risk medulloblastoma (HR-MB). The prognosis for patients with HR-MB is poor, with only 60% of patients cured. Those that are cured suffer significant long-term side effects mainly associated with radiotherapy, which can severely affect the quality of life for these patients. This trial aims to improve survival for this group of patients, while limiting the impact of side effects. The trial consists of two randomised ...

GO TO STUDY

Hydroxychloroquine (HCQ) is widely used for joint and skin disorders. It is also being investigated for the possible prevention and/or treatment of COVID19 [1]. However in some patients long-term HCQ use, for joint and skin disorders, can lead to the retina (part of the eye) becoming damaged (HCQ retinopathy), leading to irreversible blindness. In the UK, regular retinal screening is recommended for those taking HCQ, costing the NHS millions per year. Unfortunately, this only identifies the problem after it has ...

GO TO STUDY

Polycythemia vera (PV) is a rare blood cancer characterised by a high-risk of thrombosis (clotting) and haemorrhage (bleeding). Average survival in high-risk patients receiving contemporary care is 10.9 years. Current treatments include aspirin, venesection (blood drawing) and selected use of standard therapies (hydroxycarbamide (HC) or interferon alpha (IFNa)). The strategies remain less than perfect, with on-going risks of developing blood clots, bleeding, dying early due to either these events or to the disease progressing into leukaemia or a more aggressive ...

GO TO STUDY

Anonymised copies of normal and abnormal digital mammograms are collected from clinical sites. Real and simulated images of lesions are used to measure the ability of radiologists to detect breast cancer when various technical factors are adjusted.

GO TO STUDY